United States Health

Clearmind Medicine (NASDAQ:CMND) signed a definitive agreement to acquire a 51% stake in EV wireless charging company Charging Robotics for an aggregate purchase price of $2.5 million.

BioStem Technologies (NASDAQ:BSEM) announced that its VENDAJE® and VENDAJE AC® placental-derived wound care allografts have been added to existing contracts with Vizient and Premier, allowing hospitals to order the products immediately.

USA Rare Earth (NASDAQ:USAR) completed its combination with Serra Verde Group on September 3, 2026, creating an integrated rare earth and permanent magnet platform spanning Brazil, the United States, the United Kingdom, and France.

Immuron (NASDAQ:IMRN) announced an exclusive U.S. distribution agreement with Calmino group AB for PROIBS®, a digestive health product designed to support abdominal comfort and intestinal health.

Stoke Therapeutics (NASDAQ:STOK) and Biogen (NASDAQ:BIIB) reported long-term clinical data for investigational Dravet syndrome treatment zorevunersen from Phase 1/2a and open-label extension studies.

Ionis Pharmaceuticals (NASDAQ:IONS) announced that the U.S. Food and Drug Administration approved ZANVASTRO (zilganersen) for pediatric and adult patients with Alexander disease, making it the first disease-modifying treatment approved for the condition.

Milestone Pharmaceuticals (NASDAQ:MIST) received regulatory approval from China's National Medical Products Administration for its etripamil nasal spray, triggering a $2 million milestone payment.

Pharvaris (NASDAQ:PHVS) presented translational, nonclinical, and clinical data on its oral bradykinin B2 receptor antagonist deucrictibant at the Bradykinin Symposium 2026 in Berlin.

Aptevo Therapeutics (NASDAQ:APVO) reported clinical results showing that 13 of 14 evaluable frontline TP53-mutated acute myeloid leukemia (AML) patients treated with its mipletamig triplet regimen achieved clinical benefit.

CollPlant Biotechnologies (NASDAQ:CLGN) completed its acquisition of Israeli deep-tech company LightSolver, expanding into high-performance computing and photonics while continuing its existing regenerative medicine operations.

AbbVie (NYSE:ABBV) completed its acquisition of Apogee Therapeutics (NASDAQ:APGE), paying $135.11 per share in cash for an equity value of approximately $10.9 billion as of September 3, 2026.

American Healthcare REIT (NYSE:AHR) acquired eight Class A senior housing communities for approximately $696 million, expanding its presence in East Coast senior housing markets.